A 32 kDa protein isolated from human mononuclear cells is a member of the lipocortin family, a new group of Ca2+-dependent lipid-binding proteins thought to be involved in the regulation of phospholipase A2, in exocytosis and in membrane-cytoskeleton interactions. Purification of this protein was based on its ability to associate with membrane phospholipids in a Ca2+-dependent manner and its capacity to inhibit purified phospholipase A2 from pig pancreas. Using immunological detection, we show that it is present in various cells involved in the inflammatory and coagulation processes. We present extensive amino acid data that strongly suggest that this protein is identical with a recently described inhibitor of blood coagulation, with endonexin II and with lipocortin V. Sequence alignment with other known proteins show a significant degree of homology with lipocortins I and II, the substrates of the epidermal-growth-factor receptor tyrosine kinase and the oncogene pp6o8rc tyrosine kinase respectively, and with protein II. The possible physiological role of this 32 kDa lipocortin is discussed.
INTRODUCTION
Lipocortins were first described as glucocorticoidinduced secreted proteins present in many cell types and tissues, including rabbit neutrophils (Hirata et al., 1980) , rat macrophages (Blackwell et al., 1980) , rat renalmedullary interstitial cells (Cloix et al., 1983) , mouse and bovine thymus (Gupta et al., 1984) , human fibroblasts (Errasfa et al., 1985) and even in rabbit platelets (Touqui et al., 1986) . The predominant form identified was a 40 kDa protein whose major activity was to inhibit purified soluble phospholipases A2 from pig pancreas and snake venom. Other species, of 70 kDa, 30 kDa and 15 kDa, were identified and shown to be immunologically related to the 40 kDa protein (Hirata et al., 1982; Rothhut et al., 1983) , and therefore the proposed name of lipocortin was adopted (Di Rosa et al., 1984) . The anti-inflammatory effect of glucocorticoids was in part attributed to the synthesis and/or release of these proteins [for reviews see Flower et al. (1984) and Hirata (1984) ]. Moreover, a regulatory pathway controlling phospholipase A2 activity, involving protein tyrosine kinase and protein kinase C (Touqui et al., 1986) , has been proposed. Evidence for the presence of lipocortins as extracellular proteins came from their first purification to homogeneity from the peritoneal fluid of dexamethasone-treated rats . The same group purified and cloned two human phospholipase A2 inhibitors, named lipocortins I and II and exhibiting 5000 homology Huang et al., 1986) . The compared immunological properties and sequehces also showed a complete identity with another family of related Ca2+-dependent phospholipid and actin-binding proteins: calpactin II or p35 and the heavy chain of calpactin I or p36 (Glenney, 1986; Gerke & Weber, 1984) . These intracellular proteins are known as the major targets of tyrosine kinases: the epidermalgrowth-factor receptor for calpactin II (Fava & Cohen, 1984) and the retrovirally coded tyrosine kinase pp60src for p36 (Radke & Martin, 1979; Erikson & Erikson, 1980; Cooper & Hunter, 1983) . In addition, protein kinase C phosphorylates both proteins in vitro Khanna et al., 1986) , and p36 in vivo (Gould et al., 1986) .
These proteins belong to a new class of phospholipid-binding proteins found in the literature under the following names: calelectrin (Walker, 1982) , endonexin (Siidhof et al., 1984) , p68/p7O (Owens et al., 1984) , proteins I and II (Gerke & Weber, 1984) , synexin (Creutz et al., 1978) , chromobindin (Creutz, 1981) , calcimedin (Moore & Dedman, 1982) and synhibin (Pollard & Scott, 1982) . All these proteins share a characteristic structure consisting of four, or eight (p68), segments of 70-80 amino acid residues showing a significant degree of homology, containing a highly conserved consensus sequence of 17 amino acid residues Kristensen et al., 1986; Brugge, 1986; Weber & Johnsson, 1986; Weber et al., 1987; Crompton et al., 1988) . It has been proposed to give to this new class of Ca2+-and phospholipidbinding proteins the name 'annexins' (Geisow, 1986; Geisow & Walker, 1986) .
In recent work (Rothhut et al., 1984) provided evidence for this protein to be a true member of the lipocortin family. The pure protein tested on soluble phospholipases A2 (from pig pancreas and Naja naja venom) showed a dose-dependent inhibitory effect restricted to negatively charged phospholipids, but only at low substrate concentrations. These data suggested that inhibition of the enzyme by lipocortin involved its Ca2`-dependent binding to negatively charged phospholipids (Davidson et al., 1987; Haigler et al., 1987; Aarsman et al., 1987 ). An alternative, in order to explain the results at high substrate concentration, was the possible formation of an inactive enzyme-inhibitor complex, dissociated by an excess of phospholipids (Aarsman et al., 1987) . The protein was also able to inhibit purified cellular phospholipases A2 from rat platelets and rat liver mitochondria as well as endogenous phospholipase A2 in an assay using thymocytes or monocytes (C. Comera, B. Rothhut & F. Russo-Marie, unpublished work).
In the present paper we study the cellular distribution of this new 32 kDa lipocortin in different cells involved in the inflammatory process. It is a Ca2"-dependent phospholipid-binding protein. We report extensive amino acid sequence data of this 32 kDa protein. It appears that it is completely identical with a recently described inhibitor of blood coagulation (Funakoshi et al., 1987a, b; Iwasaki et al., 1987) , with another protein from human placenta, namely endonexin II Haigler et al., 1989) , and with lipocortin V (Pepinsky et al., 1988) . We also provide evidence that this protein is an inhibitor of blood coagulation and propose a mechanism involving a Ca2"-dependent interaction with phospholipids and biological membranes.
METHODS

Purification of the 32 kDa lipocortin
The 32 kDa protein was purified as described previously .
Anti-(32 kDa lipocortin) serum An antiserum against purified 32 kDa lipocortin was prepared in rabbits by using the lymph-node immunization procedure (Sigel et al., 1983 , except in one assay where the inhibitor was preincubated with the substrate and the reaction was initiated by the addition of the enzyme (I h). After the reaction was stopped, the samples were centrifuged (13000 g for 5 min), and the radioactivity of a portion of each of the supernatants containing hydrolysed [3H]oleic acid was counted by liquid-scintillation spectrometry. The percentage inhibition was calculated by comparison with the control of basal release of [3H]oleic acid without phospholipase A2 as the blank and the maximal enzyme activity in absence of inhibitory protein as the 1000 value. The pellets were washed once with incubation buffer and analysed by SDS/polyacrylamide-gel electrophoresis and Coomassie Blue staining. Controls included a reaction in which substrate was omitted (a) and an assay in which EGTA was substituted for Ca2+ in the incubation buffer (b).
(b) Binding on immobilized phospholipids. Phosphatidylserine and phosphatidylinositol immobilized on polyacrylamide (Uchida & Filburn, 1984) were equilibrated in 10 mM-Hepes/NaOH buffer, pH 7.4, containing 100 mM-KCl, 0.5 mM-dithiothreitol and either I mM-CaCl2 or 2 mM-EGTA. Portions (1,tg) of the pure protein were incubated with the bound ligands (50,u) for 2 h at 20°C and then centrifuged (5000 g for 5 min), and the supernatants and pellets were each mixed with an equal volume of electrophoresis SDS sample buffer. A sample (one-fiftieth) of each fraction was separated by SDS/polyacrylamide-gel electrophoresis (10-15 00 gradient gels) and stained with the silver reagent by using the Phast System from Pharmacia.
Coagulation assays
Activated partial thromboplastin time, expressed in seconds, was determined according to the procedure given by the manufacturer (Organon) with or without the 32 kDa lipocortin at the final concentrations indicated. Citrated normal plasma was prepared from six healthy subjects: blood (9 vol.) was drawn on trisodium citrate at 3.80% (1 vol.) and centrifuged at 2000 g for 30 min.
Specific coagulation studies of intrinsic coagulation Factors VIII, IX, XI and XII were done by a conventional method (Caen et al., 1975) : diluted normal plasma (1 / 10, 1/20 and 1/40), containing 100 ,ug of lipocortin/ml (final concentration) or not, was added to commercially available plasma depleted in coagulation Factors VIII, IX, XI or XII. Activated partial thromboplastin time was determined for all dilutions as indicated above.
Amino acid sequence analysis
The purified protein (1.4 nmol) from human mononuclear cells was carboxymethylated with 0.32 mg of iodo[I-14C]acetic acid in 100 ,ul of 0.5 M-Tris/HCl buffer, pH 8.5, containing 6 M-guanidinium chloride under Ar, after incubation for 2.5 h in the presence of 100 jtug of dithiothreitol. After 40 min reaction, the mixture was acidified with 100,ul of acetic acid, diluted with 1.8 ml of 0.1 % (v/v) trifluoroacetic acid and filtered on a Waters Associates Sep-Pak C18 cartridge. The latter was washed with 20 ml of 0.1 00 trifluoroacetic acid and the protein was eluted with 3 ml of 600 (v/v) acetonitrile in 0.1 00 trifluoroacetic acid. The yield, as indicated by amino acid analysis, was 500. For trypsin digestion, the blocked protein was dissolved into 90 ,l of 0.1 M-NH4HCO3/0. 11 mM-CaCl2, pH 7.75. After 4 h at 37°C, the sample was acidified with 20 ,u of formic acid and dried. Peptide separation was achieved on a Spheri 5 RP-8 column (100 mm x 2.1 mm) from Brownlee Laboratories, eluted at 0.2 ml/min with a gradient from 0 to 1000 between 5 %o acetonitrile in 0.05 0 trifluoroacetic acid (solvent A) and 900 acetonitrile in 0.050 trifluoroacetic acid (solvent B).
All the peptides were sequenced with an Applied Biosystems 470A gas-phase sequencer with on-line identification on an Applied Biosystems 120A h.p.l.c. system. The amounts undergoing degradation varied from 5 to 320 pmol.
RESULTS
We have first described this protein in peripheralblood mononuclear cells. In order to evaluate its expression in different types of cells, we have screened by Western blotting diverse cells involved in the inflammatory and coagulation processes, as well as a histiocytic lymphoma cell line U937. Fig. 1 Funakoshi et al. (1987a) . In control experiments the pre-immune rabbit serum was tested on the same cellular extracts and no cross-reacting bands were ever detected (results not shown).
To compare this protein with the other members of the Ca2+/lipid-binding protein family, we investigated the ability of the purified 32 kDa protein to bind to phospholipids.
In a first set of experiments we analysed the capacity of the purified protein to bind to E. coli membranes by using the phospholipase A2 assay described in the Methods section. Results in Fig. 2 show that the protein binds to the phospholipidic substrate. This binding is Ca2+-and dose-dependent and is well correlated with the phospholipase A2 iMhibition determined in the same assays. By using this procedure we could also analyse the effects of preincubation conditions. The phospholipase A2 inhibition (half-maximal) obtained when 1 ,ag of inhibitor was preincubated with the enzyme increased to 750 after preincubation of 1 ,ug of lipocortin with the substrate (Fig. 2, compare lanes g and h) . This increased inhibition is also correlated with an increased protein binding to the lipid membranes. The relative amounts of the Coomassie Blue-stained 32 kDa bands were determined by densitometric scanning (results not shown). This method confirmed the increase in the amount of protein bound to the E. coli membranes.
In a second set of experiments, we investigated the Fig. 3 show tht able to bind reversibly to immobiliz phosphatidylserine ( Fig. 3a) and p1 (Fig. 3b) , in a Ca2"-dependent manne be reversed by the addition of an exce prevented in the presence of the chel. properties are consistent with those other proteins termed annexins, reinfc the activity (inhibition of phospholipa. upon binding to negatively charged p1 presence of Ca2" (Davidson et al., 19 1987; Aarsman et al., 1987) . In order to characterize further the from peripheral-blood mononuclear amino acid sequence data. The N-tern proved to be blocked, similarly to lip( I and protein II Weber et al., 1987 . The protein was with trypsin after S-carboxymethylai were separated by h.p.l.c. (Fig. 4) and   3 The order of 253 amino acid residues was established in stretches ranging from 3 to 22 residues. The evidence thus obtained was sufficient to show a significant degree s p of homology with lipocortins I and II (Fig. 5) (Funakoshi et al., 1987a,b) The alignment shown is that proposed by Weber et al. (1987) for human lipocortins I (p35) and II (p36) and pig protein II.
The sequences of lipocortins I and II and the inhibitor of blood coagulation (IBC) are taken from Huang et al. (1986 and Iwasaki et al. (1987), and Funakoshi et al. (1987b) respectively. The upper line indicates the partial sequences determined in the present work. Peptides are numbered according to their elution position from h.p.l.c. The b series peptides were obtained upon rechromatography of poorly resolved peptides (see legend to Fig. 3) . Sequences carrying the same peptide number were obtained from a single chromatographic peak; they could easily be distinguished from one another because of different peptide amounts (e.g. T66 and T21). Lower-case letters indicate tentative identification. In addition to the peptides shown here, which were sequenced without prior knowledge of the blood coagulation inhibitor sequence, 15 more residues could be assigned in mixtures with knowledge of the published sequence. No peptide was found with a sequence that did not correspond to the published one. (Huang et al., 1986; Kristensen et al., 1986) and pig protein II (Weber et al., 1987) ; furthermore over the known portion of the sequence (80 %) they reveal complete identity with the sequence of the recently described inhibitors of blood coagulation (Iwasaki et al., 1987; Funakoshi et al., 1987b) , with the partial sequence of endonexin II Haigler et al., 1989) and with the sequence of lipocortin V (Pepinsky et al., 1988) .
Lipocortins are thought to inhibit phospholipases A2 by binding to the negatively charged phospholipid substrate in the presence of Ca2+. This mechanism may also be involved in the anticoagulant properties of the protein, since binding of -coagulation factors on phosphatidylserine is essential for initiation of the process. These inhibitions may implicate a competition between lipocortin and either phospholipase A2 or the coagulation factors for binding to phospholipids. The 32 kDa protein binds to phosphatidylinositol in a Ca2+_ dependent manner. Since this phospholipid is a substrate of phospholipase C, it would be of interest to test whether the protein has an inhibitory effect on the enzyme activity. Lipocortins are regulated by various kinases affecting their binding affinity for the phospholipids (Sheets et al., 1987; Powell & Glenney, 1987) . We have shown (Comera et al., 1989) that the 32 kDa lipocortin is not phosphorylated by the epidermalgrowth-factor-dependent tyrosine kinase and by protein kinase C in vitro.
The presence of the 32 kDa lipocortin in various cells involved in the inflammatory (monocytes, lymphocytes) Vol. 263 (Heimark & Schwartz, 1983; Stern et al., 1983) . Therefore the protein might compete with these factors for the surface phospholipids. An extracellular role for the 32 kDa protein in the inflammatory process is more questionable, since only lipocortin I has been described as a glucocorticoid-induced extracellular protein without any leader peptide. But the relationship with glucocorticoids has not yet been investigated for the 32 kDa protein. A possible association of the protein with exocytosis granules could be proposed, since such a phenomenon has been reported for the members of this family in chromaffin granules (Creutz, 1981) . Nevertheless its function as an extracellular mediator involved in inflammation and coagulation has not yet been demonstrated.
In conclusion, despite controversy in the proposed nomenclature for these different factors, a consensus is emerging from the different studies concerning some properties of this protein. It is a protein present in many cell types, except in human erythrocytes and neutrophils. It binds to phospholipids in a Ca2"-dependent manner, properties that may explain phospholipase A2-inhibitory activity. The anticoagulant activity of the protein was also in part attributed to its Ca2+-dependent phospholipid-binding properties (Iwasaki et al., 1987; Funakoshi et al., 1987a, b) and was recently described for some other-members of the family (Chap et al., 1988) . Inhibition of human Factor VIIa-tissue factor activity by placental anticoagulant protein has been described (Kondo et al., 1987) , but the mechanism of inhibition was shown to involve binding to the phospholipid portion of the tissue-factor lipoprotein. Nevertheless the physiological role of the intracellular protein is still poorly understood. One can propose a role for the 32 kDa lipocortin as an intracellular link between membrane stimulation and cellular response, or as a regulator of cytoskeleton-membrane interactions, as has been proposed for other members of this family of proteins.
